Armis Biopharma, Inc. filed a Form D with the Securities and Exchange Commission on 2025-07-10.
Armis Biopharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on July 10, 2025. The filing reports $1M sold. Its industry group is Other Health Care. It names Theodore Ziemann (Director), Steve Coder (Executive Officer, Director), Alan Ruud (Director) (SEC Form D, July 10, 2025).
Is this your company?
Sell to companies like Armis Biopharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Armis Biopharma, Inc.
Free to see. No signup.
More on the people and the money behind Armis Biopharma, Inc., from the filings we hold.
Other Health Care raises by companies based in Colorado, filed within 90 days of this one, largest first.
Get an email when Armis Biopharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Armis Biopharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch Armis Biopharma, Inc. →Get the full cited report on Armis Biopharma, Inc.
What the filing shows about Armis Biopharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Armis Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Armis Biopharma, Inc.'s address as 2401 Research Blvd, Suite 205, Fort Collins, CO 80526.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Armis Biopharma, Inc. is a registered filer with the SEC (CIK 1604801) and has filed since 2025-07-10. 1 filing is on record, the latest on 2025-07-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Armis Biopharma, Inc.'s Form D of 2025-07-10 names Theodore Ziemann, Steve Coder, Alan Ruud and 5 more as its officers, directors or promoters.
Its new offerings report $1M sold across 1 offering, as its own filings state.
Trailing twelve months. 869 filings in Other Health Care, totalled by week.
Theodore Ziemann is named as Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
Steve Coder is named as Executive Officer and Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
Alan Ruud is named as Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
Alan Smith, Ph.D. is named as Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
Christopher Rudd is named as Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
Michael Voss is named as Executive Officer and Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
Michael Litwack is named as Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
William Nelson, MD, Ph.D. is named as Director on the Form D that Armis Biopharma, Inc. filed with the SEC on 10 July 2025, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2025-07-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Armis Biopharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Armis Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Armis Biopharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Armis Biopharma, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Armis Biopharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Armis Biopharma, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/armis-biopharma-inc-form-d-25000001